Does Surgical Debulking Pituitary Adenomas Improve Responsiveness to Octreotide LAR in the treatment of acromegaly: An investigator-initated study

ID Number 03-0958

Principal Investigator(s)
Kalmon D Post

Department(s) or Division(s)

The purpose of this study is to see whether pituitary surgery (called debulking) improves the response to a medication called Sandostatin LAR in subjects with acromegaly. Sandostatin LAR (also call Octreotide LAR) is approved by the Food and Drug Administration (FDA) for the purpose it is being used in this study. It is similar to, but more effective than somatostatin, which is a naturally occurring hormone that inhibits the secretion (release) of growth hormone from the pituitary gland. Sandostatin LAR stays around in the body for a longer time that somatostatin, so that only one injection pre month (instead of 3 injections per day) is needed.

Contact Information
Kalmon D. Post, MD
(212) 241-0933

Recruiting Patients: Yes